LogicBio Therapeutics, Inc. Made Headway
Mon, Oct 03, 2022 at 07:54 PM
LogicBio Therapeutics, Inc. (LOGC:NASDAQ) soared at $2.01, representing a gain of 637.6%. On Mon, Oct 03, 2022, LOGC:NASDAQ touched a New 2-Week High of $2.01. The stock appeared on our News Catalysts scanner on Mon, Oct 03, 2022 at 06:50 PM in the 'ACQUISITION' category. From Mon, Sep 19, 2022, the stock recorded 20.00% Up Days and 9.09% Green Days
About LogicBio Therapeutics, Inc. (LOGC:NASDAQ)
LogicBio Therapeutics Inc is a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, its proprietary technology platform.
Top 10 Gainers:
- LogicBio Therapeutics, Inc. (LOGC:NASDAQ), 637.61%
- FedNat Holding Company (FNHC:NASDAQ), 308.7%
- Oblong Inc. (OBLG:NASDAQ), 167.02%
- Wearable Devices Ltd. (WLDS:NASDAQ), 48.86%
- Flexible Solutions International Inc. (FSI:NYSEMKT), 44.24%
- Myovant Sciences Ltd. (MYOV:NYSE), 36.08%
- Lottery.com Inc. (LTRY:NASDAQ), 34%
- LiveWire Group Inc. (LVWR:NYSE), 29.53%
- Engine Gaming and Media Inc. (GAME:NASDAQ), 28.87%
- Viasat, Inc. (VSAT:NASDAQ), 26.93%